Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 160

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Immunocytochemical localization of BCL‐2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy

Gee, Julia M. W., Robertson, John F. R., Ellis, Ian O., Willsher, Peter, McClelland, Richard A., Hoyle, Helen B., Kyme, Susan R., Finlay, Pauline, Blamey, Roger W., Nicholson, Robert I.·1994·International Journal of Cancer

Abstract

The protein product of the bcl‐2 gene is thought to be involved in inhibition of apoptosis; it may therefore be important in the modulation of hormonal/anti‐hormonal responsiveness exhibited by tumours. This study immunocytochemically investigates (i) relationships between bcl‐2 protein expression in primary breast cancers and other markers of prognostic and therapeutic value and (ii) associations of the bcl‐2 protein with breast cancer responsiveness to endocrine therapy. The bcl‐2 protein was found within the tumour epithelial cell cytoplasm of 32/46 breast cancer specimens; inter‐patient staining was heterogeneous. Immunostaining for steroid hormone receptors was strongly associated with that for the bcl‐2 protein, and it is thus possible that this protein, like progesterone receptor, is under oestrogen regulation via oestrogen receptor. The protein was inversely related to 2 markers of endocrine insensitivity, epidermal growth factor receptor (EGFR) and c‐erbB‐2 oncoprotein, while no associations were observed with either transforming growth factor (TGF)‐alpha or Ki‐67 proliferative status. A highly significant relationship was observed between response to endocrine therapy and the presence of bcl‐2 protein. Indeed, bcl‐2 immunostaining proved to be a more accurate predictor of response than oestrogen receptor status. Patients with elevated bcl‐2 immunostaining (particularly those who co‐expressed high oestrogen receptor levels) appeared to derive the greatest benefit from endocrine therapy. Our results are paradoxical since it was expected that the bcl‐2 protein would counteract the tumour inhibitory effects of endocrine therapies as it is thought to prevent programmed cell death.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ijc.2910590508

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 160

Metadata

Authors
Gee, J. M. W., Robertson, J. F. R., Ellis, I. O., Willsher, P., McClelland, R. A., Hoyle, H. B., Kyme, S. R., Finlay, P., Blamey, R. W., & Nicholson, R. I.
Venue
International Journal of Cancer
Publisher
Wiley
Published
1994-12
Volume
59
Issue
5
Pages
619-628
ISSN
  • 0020-7136 (ISSN-L)
  • 1097-0215
OpenAlex
W4249948852
Cited by
160
References
1
FWCI
5.15
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Immunocytochemical localization of BCL‐2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. https://app.cochat.ai/papers/10.1002/ijc.2910590508
The paper
Gee, J. M. W., Robertson, J. F. R., Ellis, I. O., Willsher, P., McClelland, R. A., Hoyle, H. B., Kyme, S. R., Finlay, P., Blamey, R. W., & Nicholson, R. I. (1994). Immunocytochemical localization of BCL‐2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. International Journal of Cancer. https://doi.org/10.1002/ijc.2910590508

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.